TissueGen

TissueGen is a private, established biotech firm pioneering a proprietary drug delivery platform that protects sensitive biologics like antibodies and growth factors during polymer encapsulation and processing. Its core technology enables the creation of extended-release formulations in various formats, including fibers, coils, and microparticles, for targeted and sustained drug delivery. With a strong IP portfolio of over 30 patents and applications, the company is positioned to address significant unmet needs in drug delivery but remains in a pre-revenue, pre-clinical development stage. Its experienced leadership team and academic spin-out heritage from UT Southwestern and UT Arlington provide a solid foundation for technology advancement.

Proprietary two-phase encapsulation platform using nanotechnology and biodegradable polymers to enable sustained release of sensitive biologics (antibodies, growth factors) and complex therapeutics in multiple formats (fibers, coils, microparticles, nanoparticles).

TissueGen competes in the crowded drug delivery space against large specialty pharma companies (e.g., Alkermes) and numerous startups. Its differentiation lies in its specific claim of preserving the activity of sensitive biologics during polymer processing, a niche but critical challenge in developing long-acting formulations of next-generation therapeutics.